

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Genichiro SOMA et al

Serial No.: 09/700,713

Filed: November 27, 2000

For : ADDITIVES FOR CRUSTACEAN OR FISH FEEDS AND FEEDS

Art Unit : 1645

Examiner : Khatol S.Shahnan-Shah

Hon. Commissioner of Patents and Trademarks

Washington, D.C. 20231

DECLARATION

Sir:

- I, Genichiro SOMA, a Japanese national, residing at 10-21, Higashitamagawa 1-chome, Setagaya-ku, Tokyo 158-0084 Japan, declares that:
- 1. I am a professor in Institute for Health Sciences of Tokushima Bunri University, Department of Immunology and Allergy, Nishihama Bouji, Yamashiro-cho, Tokushima, 770-8514, Japan.
- 2. I am an inventor of the invention of U.S. Patent Application Serial No.09/700,713 filed November 27, 2000 (hereinafter referred to as "the present invention"). I have studied the official action dated August 25, 2004 issued with respect to the present application. I have also read and studied the references cited in this official action.
- 4. I have conducted the following experiments to show the superiority of the present invention.

EXPERIMENTS

- 1. To clarify the ability for production of Tumor Necrosis factor (TNF) by various lipopolysaccharides with different molecular weights, the following lipopolysaccharides were administered intradermally into murine abdomen.
- (a) Preparation of solutions of lipopolysaccharides for intradermal administration.

Four Salmonella lipopolysaccharides and one E. coli lipopolysaccharides were used as shown in below.

- (1) S.minnesota Wild type (MW = $14000 \sim 30000$)
- (2) R5 (MW = about 3600)
- (3) R7 (MW = about 3400)
- (4) R595 (MW = about 2700)
- (5) lipopolysaccharide of E. coli 0127 : B8 (MW = 10000 \sim 60000)

Each of lipopolysaccharides was dissolved in saline solution under sterile conditions at 2mg/ml concentration. Further, solutions having concentrations of 0.2 mg/ml and 0.02 mg/ml were also prepared by dilution of the 2mg/ml solution with addition of saline solution.

(b) Administration of lipopolysaccharide to mouse and collection of serum

Mouse (two or three mouse per group) was intradermally administered 50 μ l of each of the above lipopolysaccharide solutions into abdomen, and only saline solution (for control). After 90 minutes, blood was collected from the mouse, and blood

serum was separated. TNF activities in serum were measured by L929 cell cytotoxicity assay.

(c) Results of the test

The results were shown in Table 1 and Fig.1.

Lipopolysaccharide R5, R7 and R595 having a low molecular weight less than 4000 demonstrated lower TNF inducting activity than lipopolysaccharide of E. coli (MW = 10000 ~ 60000) and S. minnesota Wild type (MW = 14000 ~ 30000) having a high molecular weight.


(d) Conclusion

Lower molecular weight of lipopolysaccharides does not correlate to high biological activity of lipopolysaccharide. It depends on the kinds of lipopolysaccharides. In other word, lipopolysaccharide of a low molecular weight does not necessarily have high biological activity depending on the kinds of lipopolysaccharides.

Table 1

sample	dose (μg/mouse)	TNF (u/ml)			average	standard deviation
Saline	0	0	0		0	
E.coli	1μg	0.15	0.45	0.61	0.40	0.13
	10 µg	1.39	4.06		2.73	0.89
	100µg	3.14	12.15		7.65	3.00
S.minnesota Wild type	1μg	0.67	0.47	0.64	0.59	0.06
	10 µg	3.51	3.68		3.60	0.06
	100µg	3.94	4.51		4.23	0.19
R5	1 µ g	0	0	0	0	0
	10 μ g	0	0.45		0.23	0.15
	100 µg	1.87	1.69		1.78	0.06
R595	1μ g	0	0	0	0	0
	10 µg	0	0		0	0
	100µg	1.13	0.81		0.97	0.11
R7	1 μ g	0	0	0	0	0
	10 μ g	0	0.11		0.06	0.04
	100 μ g	0.22	0.5		0.36	0.09

Fig. 1



CONSIDERATION OF THE RESULTS

It can be concluded from the above that lipopolysaccharide of a low molecular weight does not correlate to its biological activity.

Namely, lipopolysaccharide of a low molecular weight does not necessarily have high biological activity depending on the kinds of lipopolysaccharides.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Executed this 17 th day of November, 2004.

Genichiro SOMA

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.